MGI Tech, a developer of core tools and technologies for life sciences, announced the acquisition of STOmics and CycloneSEQ as part of a strategy to integrate long-read sequencing, short-read sequencing, and spatial omics technologies into a unified platform. The move advances MGI’s “SEQALL+GLI+Omics” strategy and positions the company as a provider of integrated solutions spanning multiple genomic analysis technologies.
The acquisition enables MGI to bring spatial biology and nanopore sequencing technologies fully in-house, strengthening its product portfolio and expanding its capabilities across genomic research workflows. By combining these technologies with its existing sequencing platforms and generative lab intelligence capabilities, the company aims to deliver a more comprehensive solution for researchers working with complex biological datasets.
STOmics, founded in April 2024, developed the proprietary Stereo-seq technology designed for spatial multi-omics analysis. The platform provides a large field of view, nano-scale resolution, and unbiased whole-transcriptome capture while enabling integrated multi-omics studies. Researchers have used the technology across several areas of biological research, including developmental biology, organ atlas mapping, neuroscience, and digital pathology.
According to the announcement, Stereo-seq has already contributed to more than 60 publications in leading scientific journals, including Cell, Science, Nature, and Cell Research. The technology is designed to work with MGI’s patented DNBSEQ sequencing platform, with Stereo-seq libraries sequenced on the company’s flagship G400 and T7 instruments to generate high-quality genomic data.
With the integration of STOmics’ spatial technologies, MGI plans to offer more accessible spatial-temporal multi-omics workflows, enabling researchers to gain deeper three-dimensional insights into biological processes and tissue architecture.
CycloneSEQ, founded in March 2024, commercialized nanopore-based long-read sequencing technology and developed two sequencing platforms: the G100-ER for lower-throughput applications and the G400-ER for higher-throughput sequencing needs. The G100-ER system has received CE marking under the European Union’s In Vitro Diagnostic Regulation, indicating readiness for regulated clinical markets in Europe.
MGI’s DNBSEQ short-read sequencing technology is designed to complement CycloneSEQ’s long-read nanopore sequencing systems. Together, the integrated technologies provide researchers with a toolkit that supports both highly accurate short-read sequencing and long-read sequencing for analyzing complex genomic structures.
Prior to the acquisition, both STOmics and CycloneSEQ maintained close collaborations with MGI, with the company holding exclusive global distribution licenses for their reagents and products. With the businesses now integrated under MGI, the company aims to streamline product development and deliver a unified ecosystem covering sequencing instruments, reagents, spatial omics technologies, and AI-driven laboratory intelligence tools.
MGI said the consolidation of short-read sequencing, long-read sequencing, spatial omics, and generative lab intelligence technologies under one organization is expected to improve operational efficiency, strengthen customer support capabilities, and enhance the long-term value delivered to research partners worldwide.
Founded in 2016, MGI develops and manufactures life science instruments, reagents, and related technologies used across fields including precision medicine, agriculture, and healthcare. The company provides digital systems and multi-omics solutions for research and clinical applications and operates research, manufacturing, and service facilities across six continents.
MGI is also among the companies capable of independently developing and mass-producing clinical-grade gene sequencers across a wide range of throughput levels, spanning from gigabase to terabase-scale sequencing systems.
